CVRx Inc. (CVRX)
CVRx Inc. (CVRX) Stock Price, Analysis & Data
| Bid | 1.89 |
| Market Cap | 69M |
| Revenue (ttm) | 61.19M |
| Net Income (ttm) | -51.97M |
| Beta | 0.82 |
| EPS (ttm) | -1.97 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.38 |
| P/B (ttm) | 3.46 |
| P/S (ttm) | 1.13 |
| Earnings Date | Nov 5, 2026 |
| Ask | 3.26 |
| Volume | 420,171 |
| Avg. Volume (20D) | 616,909 |
| Open | 2.55 |
| Previous Close | 2.60 |
| Day's Range | 2.50 - 2.69 |
| 52-Week Range | 2.20 - 11.30 |
| Analyst | Buy |
| Price Target | 4.5 (73.75%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CVRX
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex act...
Financial Performance
In 2025, CVRx's revenue was 56.65M, an increase of 10.45% compared to the previous year's 51.29M. Earnings were -53.31M, a decrease of -11.1%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for CVRX stock is "Buy". The 12-month stock price forecast is 4.5, which is upside of 73.75% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
